Finch Therapeutics announced that it has entered into a clinical trial agreement with Brigham and Women’s Hospital for the evaluation of CP101 in ulcerative colitis. The company also announced updates to its license agreement with the University of Minnesota. Under the clinical trial agreement, Brigham and Women’s Hospital will conduct an investigator-sponsored trial that is designed to compare two doses of CP101 in patients with mild-to-moderate ulcerative colitis. The study is designed to generate data on safety, pharmacokinetics, pharmacodynamics and clinical efficacy, and aims to build on a growing body of evidence supporting the role of the microbiome in improving outcomes for patients suffering from ulcerative colitis. Topline data from this clinical study is anticipated in 2025. The company also announced that it has amended its license agreement with the University of Minnesota, through which Finch has exclusively licensed 13 issued patents and 7 patent applications covering specific approaches to formulations comprising human fecal microbes, methods of increasing microbiota diversity, and methods of decreasing the relative abundance of certain bacteria. A key feature of the amendment allows Finch to satisfy certain performance milestones through sublicensing agreements, aligning with Finch’s new strategic focus on collaborations and partnerships.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on FNCH:
- Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement
- Finch Therapeutics price target lowered to $7 from $17 at H.C. Wainwright
- Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates